Eight rhesus macaques between 127 and 132 days of gestation had catheters implanted into maternal femoral vessels and the amniotic fluid cavity and were placed in a vest-and-tether system for chronic catheter maintenance. Uterine activity was continuously recorded, and paired maternal arterial blood and amniotic fluid samples were collected at 0900 h (AM) and 2100 h (PM) until delivery and analyzed for prostaglandin metabolites (PGFM and PGEM-II). A circadian pattern in uterine contractility was observed, with peak activity occurring between 1900 and 0100 h (p less than 0.001). No significant AM-PM differences were observed in maternal plasma PGFM (240 +/- 24 AM vs. 273 +/- 35 PM) or PGEM-II (537 +/- 41 AM vs. 484 +/- 34 PM) or amniotic fluid PGFM (360 +/- 72 AM vs. 287 +/- 70 PM) or PGEM-II (1626 +/- 383 AM vs. 1771 +/- 431 PM). All values represent mean +/- SEM, pg/ml. Additional samples were collected at 3-h intervals for 24 h at selected times during the study. This more intensive sampling protocol also failed to reveal any significant time trends in maternal plasma or amniotic fluid prostaglandins. Despite the lack of AM-PM differences, amniotic fluid PGFM and PGEM-II increased significantly as delivery approached (p less than 0.01). It appears that circadian uterine activity is not related to changes in maternal plasma or amniotic fluid prostaglandins. Although prostaglandins are responsible for the progression of labor, other factors may be involved in the generation of uterine activity rhythms prior to the initiation of labor.

1982-11-01·Prostaglandins, Leukotrienes and Medicine

A sensitive radioimmunoassay for 11-deoxy-13,14-d i h yd ro-15-k eto-11,16-cycloprostaglandin E2: Application as an index of prostaglandin E2 biosynthesis during human pregnancy and parturition

Article

作者: Cox, K. ; Ebenhack, K. ; Mitchell, M. D. ; Kraemer, D. L. ; Strickland, D. M. ; Cutrer, S.

A radioimmunoassay for 11-deoxy-13, 14-dihydro-15-keto-11, 16-cycloprostaglandin E2 (PGEM-II) is described. At pH 10.5, in the presence of albumin, 13, 14-dihydro-15-keto-prostaglandin E2 (PGEM-I) is transformed quantitatively into PGEM-II. Hence, after plasma samples are subjected to this transformation procedure, PGEM-II can be measured in such samples and be a true reflection of PGEM-I production and thereby prostaglandin E2 (PGE2) biosynthesis. The antiserum raised against PGEM-II is minimally cross-reactive with all prostaglandins tested (less than 0.01%). The mean least detectable mass of PGEM-II is 0.8 pg and the mean mass of added PGEM-II required to displace zero-point binding by 50% is 16.6 pg. The assay meets all the standard criteria for accuracy, reproducibility and parallelism. Concentrations of PGEM-II measured by this assay in peripheral plasma from men and nonpregnant women are similar to those reported for PGEM-I after measurements by gas chromatography - mass spectrometry. Plasma concentrations of PGEM-II in men were greater than in nonpregnant women. PGEM-II in increased concentration was found in early pregnancy although concentrations declined in the third trimester until labor when a significant increase was found. Concentrations of PGEM-II in umbilical venous plasma were significantly greater than those in maternal plasma.

100 项与 TRM-88 相关的药物交易

登录后查看更多信息